|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TIMM17A |
Gene summary for TIMM17A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TIMM17A | Gene ID | 10440 |
| Gene name | translocase of inner mitochondrial membrane 17A | |
| Gene Alias | TIM17 | |
| Cytomap | 1q32.1 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | Q99595 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10440 | TIMM17A | LZE2T | Human | Esophagus | ESCC | 3.13e-04 | 1.17e+00 | 0.082 |
| 10440 | TIMM17A | LZE4T | Human | Esophagus | ESCC | 6.13e-17 | 5.45e-01 | 0.0811 |
| 10440 | TIMM17A | LZE5T | Human | Esophagus | ESCC | 8.79e-03 | 3.38e-01 | 0.0514 |
| 10440 | TIMM17A | LZE7T | Human | Esophagus | ESCC | 1.64e-07 | 9.13e-01 | 0.0667 |
| 10440 | TIMM17A | LZE8T | Human | Esophagus | ESCC | 2.27e-08 | 2.59e-01 | 0.067 |
| 10440 | TIMM17A | LZE20T | Human | Esophagus | ESCC | 2.38e-07 | 1.54e-01 | 0.0662 |
| 10440 | TIMM17A | LZE22D1 | Human | Esophagus | HGIN | 8.26e-05 | -3.58e-02 | 0.0595 |
| 10440 | TIMM17A | LZE24T | Human | Esophagus | ESCC | 8.04e-10 | 3.78e-01 | 0.0596 |
| 10440 | TIMM17A | LZE6T | Human | Esophagus | ESCC | 5.46e-04 | 1.46e-01 | 0.0845 |
| 10440 | TIMM17A | P2T-E | Human | Esophagus | ESCC | 6.92e-24 | 6.27e-01 | 0.1177 |
| 10440 | TIMM17A | P4T-E | Human | Esophagus | ESCC | 7.77e-52 | 1.40e+00 | 0.1323 |
| 10440 | TIMM17A | P5T-E | Human | Esophagus | ESCC | 3.60e-52 | 1.39e+00 | 0.1327 |
| 10440 | TIMM17A | P8T-E | Human | Esophagus | ESCC | 5.44e-23 | 4.57e-01 | 0.0889 |
| 10440 | TIMM17A | P9T-E | Human | Esophagus | ESCC | 3.23e-27 | 9.10e-01 | 0.1131 |
| 10440 | TIMM17A | P10T-E | Human | Esophagus | ESCC | 1.51e-57 | 1.13e+00 | 0.116 |
| 10440 | TIMM17A | P11T-E | Human | Esophagus | ESCC | 2.54e-13 | 8.71e-01 | 0.1426 |
| 10440 | TIMM17A | P12T-E | Human | Esophagus | ESCC | 1.06e-15 | 4.80e-01 | 0.1122 |
| 10440 | TIMM17A | P15T-E | Human | Esophagus | ESCC | 2.46e-27 | 7.62e-01 | 0.1149 |
| 10440 | TIMM17A | P16T-E | Human | Esophagus | ESCC | 9.20e-28 | 8.27e-01 | 0.1153 |
| 10440 | TIMM17A | P17T-E | Human | Esophagus | ESCC | 1.36e-08 | 4.12e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007058516 | Prostate | BPH | protein localization to mitochondrion | 43/3107 | 125/18723 | 9.29e-07 | 1.70e-05 | 43 |
| GO:001703810 | Prostate | BPH | protein import | 62/3107 | 206/18723 | 9.72e-07 | 1.77e-05 | 62 |
| GO:00516049 | Prostate | BPH | protein maturation | 80/3107 | 294/18723 | 2.64e-06 | 4.23e-05 | 80 |
| GO:000662616 | Prostate | BPH | protein targeting to mitochondrion | 34/3107 | 100/18723 | 1.64e-05 | 2.05e-04 | 34 |
| GO:00164855 | Prostate | BPH | protein processing | 62/3107 | 225/18723 | 2.22e-05 | 2.67e-04 | 62 |
| GO:199054210 | Prostate | BPH | mitochondrial transmembrane transport | 34/3107 | 102/18723 | 2.63e-05 | 3.10e-04 | 34 |
| GO:00718067 | Prostate | BPH | protein transmembrane transport | 19/3107 | 59/18723 | 2.37e-03 | 1.29e-02 | 19 |
| GO:00650024 | Prostate | BPH | intracellular protein transmembrane transport | 16/3107 | 51/18723 | 6.72e-03 | 3.02e-02 | 16 |
| GO:007259417 | Prostate | Tumor | establishment of protein localization to organelle | 151/3246 | 422/18723 | 3.19e-20 | 2.83e-17 | 151 |
| GO:004586219 | Prostate | Tumor | positive regulation of proteolysis | 124/3246 | 372/18723 | 3.46e-14 | 4.31e-12 | 124 |
| GO:000660519 | Prostate | Tumor | protein targeting | 109/3246 | 314/18723 | 6.11e-14 | 7.30e-12 | 109 |
| GO:000683917 | Prostate | Tumor | mitochondrial transport | 84/3246 | 254/18723 | 7.17e-10 | 3.57e-08 | 84 |
| GO:007058517 | Prostate | Tumor | protein localization to mitochondrion | 47/3246 | 125/18723 | 5.20e-08 | 1.58e-06 | 47 |
| GO:007265517 | Prostate | Tumor | establishment of protein localization to mitochondrion | 45/3246 | 120/18723 | 1.09e-07 | 2.89e-06 | 45 |
| GO:001703814 | Prostate | Tumor | protein import | 66/3246 | 206/18723 | 1.78e-07 | 4.38e-06 | 66 |
| GO:000662617 | Prostate | Tumor | protein targeting to mitochondrion | 37/3246 | 100/18723 | 2.07e-06 | 3.56e-05 | 37 |
| GO:005160415 | Prostate | Tumor | protein maturation | 81/3246 | 294/18723 | 7.58e-06 | 1.13e-04 | 81 |
| GO:199054217 | Prostate | Tumor | mitochondrial transmembrane transport | 36/3246 | 102/18723 | 9.84e-06 | 1.43e-04 | 36 |
| GO:001648512 | Prostate | Tumor | protein processing | 63/3246 | 225/18723 | 4.40e-05 | 4.98e-04 | 63 |
| GO:007180614 | Prostate | Tumor | protein transmembrane transport | 19/3246 | 59/18723 | 3.94e-03 | 2.00e-02 | 19 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TIMM17A | SNV | Missense_Mutation | rs750416279 | c.253G>A | p.Gly85Arg | p.G85R | Q99595 | protein_coding | tolerated(0.36) | benign(0.113) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| TIMM17A | SNV | Missense_Mutation | c.17N>C | p.Arg6Pro | p.R6P | Q99595 | protein_coding | deleterious(0.01) | possibly_damaging(0.747) | TCGA-BH-A18K-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| TIMM17A | SNV | Missense_Mutation | rs756338629 | c.112C>T | p.Arg38Cys | p.R38C | Q99595 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TIMM17A | SNV | Missense_Mutation | c.119N>A | p.Ser40Tyr | p.S40Y | Q99595 | protein_coding | deleterious(0) | possibly_damaging(0.815) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TIMM17A | SNV | Missense_Mutation | c.98N>T | p.Ala33Val | p.A33V | Q99595 | protein_coding | tolerated(0.48) | possibly_damaging(0.744) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| TIMM17A | SNV | Missense_Mutation | rs202092277 | c.386N>T | p.Ala129Val | p.A129V | Q99595 | protein_coding | tolerated(1) | benign(0.017) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TIMM17A | SNV | Missense_Mutation | novel | c.140G>T | p.Arg47Ile | p.R47I | Q99595 | protein_coding | deleterious(0.01) | probably_damaging(0.987) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| TIMM17A | SNV | Missense_Mutation | novel | c.209N>A | p.Gly70Glu | p.G70E | Q99595 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-B5-A0JU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TIMM17A | SNV | Missense_Mutation | rs756338629 | c.112N>T | p.Arg38Cys | p.R38C | Q99595 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| TIMM17A | SNV | Missense_Mutation | rs757756350 | c.88N>G | p.Ile30Val | p.I30V | Q99595 | protein_coding | tolerated(0.78) | benign(0.026) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |